Nothing Special   »   [go: up one dir, main page]

Li et al., 2012 - Google Patents

Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes

Li et al., 2012

View HTML
Document ID
17920774291420051463
Author
Li C
Baaten B
Bradley L
Publication year
Publication venue
Journal of molecular cell biology

External Links

Snippet

Abstract Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing β- cells in the pancreatic islets. There is an immediate need to restore both β-cell function and immune tolerance to control disease progression and ultimately cure T1D. Currently, there is …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Similar Documents

Publication Publication Date Title
Yu et al. Harnessing the power of regulatory T‐cells to control autoimmune diabetes: overview and perspective
Roep et al. Immune modulation in humans: implications for type 1 diabetes mellitus
Gitelman et al. Regulatory T cell therapy for type 1 diabetes: May the force be with you
Jeffery et al. Clinical potential of regulatory T cell therapy in liver diseases: an overview and current perspectives
Monti et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells
Marek‐Trzonkowska et al. Clinical application of regulatory T cells in type 1 diabetes
Liberal et al. Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease
Jiang et al. An integrated view of suppressor T cell subsets in immunoregulation
Lohr et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens
Hu et al. Regulatory T cells in kidney disease and transplantation
Wu et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model
Feng et al. Interferon-γ conditioning ex vivo generates CD25+ CD62L+ Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy
Lee et al. Thymic and peripheral differentiation of regulatory T cells
Huynh et al. Signals and pathways controlling regulatory T cells
Perdigoto et al. Inducing and administering Tregs to treat human disease
Battaglia et al. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes
Spence et al. Restoring regulatory T cells in type 1 diabetes
Zhang et al. Adoptive cell therapy using antigen-specific CD4− CD8− T regulatory cells to prevent autoimmune diabetes and promote islet allograft survival in NOD mice
Li et al. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes
Vandenbark et al. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?
Thompson et al. Autologous regulatory T cells for the treatment of type 1 diabetes
Vlad et al. CD8+ T suppressor cells and the ILT3 master switch
Landwehr-Kenzel et al. Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy
Safinia et al. Adoptive regulatory T cell therapy: challenges in clinical transplantation
Monti et al. Interleukin-7 and type 1 diabetes